top of page
AcouSort logo on Microfluicids Innovation Hub website.
Open Call Project
AcouSome: Revolutionizing Exosome Diagnostics with Acoustic Separation

Integrated polymer chip for acoustic separation of Extracellular Vesicles

Exosomes, tiny extracellular vesicles, are unlocking new potentials in diagnostics for various diseases, including cancer, cardiology, and infectious diseases. However, isolating these nanoscale particles from blood samples is currently labor-intensive and complex. AcouSome, an initiative by AcouSort, is set to change this by introducing an efficient, automated, and precise solution for exosome isolation.

AcouSome, funded by the EIC Transition, integrates acoustic separation and trapping into a single, automated, chip-based platform. Leveraging advanced acoustofluidic methods developed by Lund University, this technology separates plasma from blood and efficiently captures exosomes. Unlike existing manual and costly techniques, AcouSome utilizes cost-effective polymer chips that provide stable performance suitable for clinical applications.

Why AcouSome Stands Out

  • Efficiency & Purity: Rapidly isolates exosomes with high purity, ready for detection and analysis.

  • Stability & Robustness: Minimizes human error and variability, ensuring reliable diagnostic outcomes.

  • Speed & Integration: Designed for quick point-of-care testing and high-throughput laboratory diagnostics.

  • Automation & Scale: Eliminates labor-intensive processes, facilitating wide-scale diagnostic use.

  • Cost-effectiveness: Optimized for high-throughput diagnostic samples while being cost-efficient.

The Market & Scalability

AcouSome is not just a product but a versatile platform aimed at the in-vitro diagnostics market, which was valued at 96 billion USD in 2021 and is projected to reach 149 billion USD by 2028. This technology promises to revolutionize the market, providing scalable and disposable diagnostic devices.

Revolutionizing Exosome Diagnostics with AcouSome's Acoustic Separation Technology

AcouSort has approached MIH for assistance in transferring their microfluidic chip from glass to polymer to achieve high-volume manufacturing while maintaining chip performance.

Send your inquiry today to join the forefront of microfluidic innovation!

Photo of AcouSort's acoustofluidic chip for cell trapping under a microscope.

Develop an integrated polymer chip for efficient, automated acoustic separation of exosomes.
Ensure high purity and stable performance suitable for clinical diagnostics.
Optimize manufacturing techniques for scalable and cost-effective production.


Technical Management: MIH oversees project coordination and aligns product requirements.
Chip Design and Prototyping: MIC (Micronit b.v.) focuses on rapid prototyping and developing the post-processing strategy for injection-molded samples.
Injection Molding Production: RKT, as a subcontractor, handles the manufacture of the injection molding tools and the actual production of the chips.
Metrology and Quality Assessment: JR (Joanneum Research) focuses on quality control and assessment of the manufactured chips.


Compatibility with analyte fluids and acoustic properties.
Reliable performance under clinical conditions.
Scalable manufacturing processes like injection molding.

The Role of the #MIHfamily

  • Microfluidics Innovation Hub (MIH): Providing project management and support in fluidic chip design.

  • Micronit b.v. (MIC): Specializing in chip design, rapid prototyping, and post-processing strategies.

  • RKT (subcontractor): Handling the injection molding process and tool manufacturing.

  • Joanneum Research (JR): Focuses on metrology and quality assessment of the produced chips.

Partners Involved

Explore More

Stay tuned as we continue to innovate and refine our approach to exosome diagnostics. Discover how AcouSome's acoustic separation technology is making a significant impact in the field of medical diagnostics.

Services and Technologies

AcouSort's collaboration with MIH and partners is vital in transforming AcouSome from a promising prototype into a robust, market-ready product, advancing the field of exosome diagnostics.

This project has received funding from the European Union’s HORIZON 2020 research & innovation programme under grant agreement no. 862092.

bottom of page